Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Jun 29, 2015 12:28pm

81 Views

Post# 23877277

RE:RE:RE:RE:RE:RE:COULD NOT ZENITH DO THIS??

JK, you wrote "I THINK SEVERAL OF ITS EMPLOYEES FILED PATENTS FOR THIS AGENT AND FILED THEM BEFORE THERE THEN EMPLOYER ZENITH. THE EMPLOYEES WERE LET GO BY ZENITH OR RVX. THEY NO DOUBT ASSIGNED THE SUBJECT PATENTS TO ANOTHER COMPANY CAUSING ZENITH TO ABANDON FURTHER DEVELOPE OF THIS DRUG."

Read more at https://www.stockhouse.com/companies/bullboard/t.rvx/resverlogix-corp#1hAG1rKKTce68hXo.99

So just because a former employee was on the Zenith patent leads you to make these statements? C'mon, you have to have more than that. Otherwise, still all speculation.

Bullboard Posts

Visionstate set to leverage success in the U.S. market